Secondary endpoints of the trial comprise the variation in perimetric mean deviation, papilloedema, and monthly headache days over 24 weeks. Credit: Mehrpouya H on Unsplash.

The New Zealand Medicines and Medical Devices Safety Authority (MEDSAFE) has granted approval to Invex Therapeutics to begin the Phase III IIH EVOLVE clinical trial of Presendin (sustained release (SR) Exenatide) to treat idiopathic intracranial hypertension (IIH) patients. 

The company also received the Health and Disability Ethics Committee’s approval, which is needed to carry out trials of new therapies in the country.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

To be carried out at up to 40 study centres across the globe, the trial will enrol 240 subjects with recently diagnosed IIH.

The randomised, placebo-controlled, double-blind, multi-centre trial will evaluate the efficacy and safety of Presendin compared to a placebo, given once a week for more than 24 weeks. 

The variation in intracranial pressure (ICP), as evaluated by lumbar puncture, from baseline to 24 weeks is the trial’s primary endpoint. 

Secondary endpoints of the trial comprise the variation in perimetric mean deviation (PMD), papilloedema, and monthly headache days over 24 weeks.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

A subcutaneous, sustained-release (SR) Exenatide microsphere formulation, Presendin was initially developed by Peptron.

Invex signed an exclusive partnership, manufacturing, and supply agreement with Peptron in September last year for Presendin in IIH for all key markets, excluding South Korea.

A small peptide and a synthetic form of the GLP-1 agonist exendin-4, Exenatide is approved to treat type 2 diabetes.

Invex executive director and chief scientific officer professor Alex Sinclair said: “We are pleased to be recruiting patients for the IIH EVOLVE clinical trial in New Zealand, where specialist clinicians have conveyed to the Invex team an interest in participating in our trial as they seek new effective therapies to treat IIH, where the incidence is rising, consistent with increasing rates of obesity in the general population.”

In July this year, the company received approval in Australia to commence the IIH EVOLVE trial of Presendin for IIH in the country.